Beta blockers theoretically benefit coronary artery disease by reducing myocardial demand and reducing potential for ischemia and arrhythmia. This has been demonstrated conclusively with certain beta blockers (eg. Carvedilol). Other beta blockers, like Metoprolol have not been conclusively shown to reduce mortality and recurrent events, but most regard beta blocker benefits as a class effect.
POSTED BY: Steven Ajluni, MD